Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II study.

Twenty-four patients with recurrent or metastatic cervical cancer were treated with vindesine (VDS) (2 mg/m2) on 2 subsequent days per week. Twenty patients were evaluable for response. There were six partial responses (30%) and no complete responses. The median remission duration was 6.5 months. The results indicate that VDS is active in the treatment of cervical cancer. Dose-limiting toxic effects were leukopenia and peripheral neuropathy. VDS should be considered in the treatment planning of combination chemotherapy for cervical cancer.